Abstract

Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating

Author(s): Martin Matt

Issue: Jul/Aug 2018 - Volume 22, Number 4

Page(s): 303-312

Download in electronic PDF format for $75

Abstract

Compounding pharmacists must separately and collectively evaluate multiple aspects of a compounded sterile preparation when determining their beyond-use date. Considerations include the microbiological risk level, storage temperature, chemical stability, batch size, and whether or not a sterility test will be performed. The United States Pharmacopeia Chapter <797> provides guidance on the maximum beyond-use date allowed solely based on the microbiological risk level associated with the compounding of a sterile preparation. Compounders should select the shortest beyond-use date between the risk-level based beyond-use date and the chemical stability of the compound. When compounding pharmacists intend to provide a compounded sterile preparation with a beyond-use date that exceeds the risk-level based recommendations in United States Pharmacopeia Chapter <797>, they must ensure that their formulations are sterility tested in compliance with United States Pharmacopeia Chapter <71>. United States Pharmacopeia Chapter <71> compliance includes conducting method suitability that is applicable to the strength and batch size that they plan to prepare. Chemical stability must be a separate consideration for each formulation.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2018 Pg. 303-312	Basics of Sterile Compounding: Criteria for Determining Beyond-use Dating Author(s): Martin Matt
Nov/Dec 2021 Pg. 491-496	Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 12: United States Pharmacopeia Chapters Referenced in the Current United States Pharmacopeia Chapter <797> Pharmaceutical Compounding -- Sterile Preparations Author(s): Allen Loyd V Jr
May/Jun 2010 Pg. 232-238	Basics of Compounding: Considerations for Implementing USP Chapter <797> -- Sterile Preparations, Part 19: Storage and Beyond-Use Dating, Maintaining Sterility, Purity, and Stability of Dispensed and Distributed Compounded Sterile Preparations Author(s): Okeke Claudia C, Allen Loyd V Jr
Jul/Aug 2008 Pg. 344-353	Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 8; Stability and Beyond-Use Dating Author(s): Allen Loyd V Jr, Okeke Claudia C
Mar/Apr 2020 Pg. 92	PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1 Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 180	PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2 Author(s): Allen Loyd V Jr
Nov/Dec 2008 Pg. 524-528	Quality-Control Analytical Methods: Overview of Beyond-Use Dating for Compounded Sterile Preparations Author(s): Trissel Lawrence A
May/Jun 2008 Pg. 252-257	Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 7: Microbial Contamination Risk Levels, 12-Hour Use, and Immediate Use Author(s): Allen Loyd V Jr, Okeke Claudia C
Nov/Dec 2012 Pg. 471-474	Beyond-use Date: Establishment and Maintenance Author(s): Osteen Richard
Mar/Apr 2021 Pg. 115-124	Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice Author(s): Kelley Brian
Jan/Feb 2021 Pg. 73-81	Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Sep/Oct 2007 Pg. 404-410	Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 3: Risk Levels Author(s): Allen Loyd V Jr, Okeke Claudia C
Mar/Apr 2005 Pg. 136-138	Quality-Control Analytical Methods: Chemical Testing Aspects of USP <797> for Compounded Sterile Preparations Author(s): Kupiec Thomas C
Jul/Aug 2007 Pg. 302-305	Update on the Proposed Revision Process for United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations Author(s): Okeke Claudia C
Jan/Feb 2012 Pg. 6-10	Misinterpretation of United States Pharmacopeia Chapter <797> Author(s): McElhiney Linda F
Jan/Feb 2006 Pg. 36-39	Basics of Compounding: Application of the United States Pharmacopeia Bacterial Endotoxins Test to Compounded Sterile Preparations Author(s): Dawson Michael F
Mar/Apr 2008 Pg. 136-144	Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 6: 2008 Revisions to Chapter <797> Author(s): Allen Loyd V Jr, Okeke Claudia C
Nov/Dec 2011 Pg. 488-496	Basics of Compounding: Implementing United States Pharmacopeia Chapter <795> Pharmaceutical Compounding--Nonsterile Preparations, Part 3 Author(s): Allen Loyd V Jr
May/Jun 2008 Pg. 216-229	Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards Author(s): Kastango Eric S
Jan/Feb 2008 Pg. 54-60	Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 5: Verification of Accuracy, Sterility, and Sterilization of Compounded Preparations Author(s): Allen Loyd V Jr, Okeke Claudia C